LLY (Eli Lilly and Company) — Investment Research Report
LLY (Eli Lilly and Company) — Investment Research Report
Date: May 13, 2026 | Price: $1,006.46 | Market Cap: $898B
Phase 1 — Macro & Industry Context
Eli Lilly is the world's largest pharmaceutical company by market cap, driven by its dominance in the GLP-1 (glucagon-like peptide-1) receptor agonist class — the most significant breakthrough in obesity and diabetes treatment in decades. The company generates over $72B in TTM revenue with tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity) leading extraordinary growth.
Economic cycle: LLY is largely recession-resistant — GLP-1 drugs treat chronic conditions with expanding payer coverage. The obesity and diabetes markets are structural growth drivers independent of economic cycles.
Industry TAM: The global GLP-1 market is projected to reach $150-200B+ annually by decade's end. Obesity affects 40%+ of U.S. adults; only ~5% currently on GLP-1 therapy. The addressable market expansion is in early innings.
Regulatory landscape: U.S. Inflation Reduction Act (IRA) creates pricing headwinds for negotiated drugs starting 2026, but GLP-1s face relatively limited immediate impact due to patent coverage. European approvals (Kisunla) expanding.
Capital flows: 90% institutional ownership reflects confidence in the franchise. The stock has pulled back ~11% from its 52-week high ($1,134 → $1,006), offering a better entry.
Net verdict: STRONG TAILWIND — GLP-1 is the largest pharmaceutical opportunity in a generation.
Phase 2 — Business Model & Moat
Revenue Model
LLY's revenue is concentrated in its GLP-1 franchise:
- Mounjaro (tirzepatide for T2D): Q1 2026 revenue $8.7B (+125% YoY)
- Zepbound (tirzepatide for obesity): Continuing strong growth trajectory
- Foundayo: Newly approved maintenance obesity treatment
- Kisunla (donanemab): Alzheimer's treatment, growing franchise
- Other pharmaceuticals: Cancer, immunology, neuroscience portfolio
Moat Analysis
- Dual mechanism advantage: Tirzepatide is the only GIP + GLP-1 dual agonist, showing superior weight loss vs. Novo's semaglutide (GLP-1 only) in head-to-head SURMOUNT trials
- Manufacturing moat: Aggressive capacity expansion — doubling over 2-3 years. Competitors (especially Novo) have faced supply constraints that LLY is exploiting
- Clinical data moat: Deepest and most comprehensive clinical program for tirzepatide across multiple indications (obesity, diabetes, MASH, sleep apnea, HFpEF)
- Orforglipron (oral GLP-1): Phase 3 oral obesity drug could be major convenience breakthrough
Moat Verdict: VERY WIDE
Key Risks to Business Model
- Competition from Novo, Amgen, Pfizer, Viking, Structure Therapeutics
- IRA pricing pressure on negotiated drugs
- Clinical/regulatory risk on pipeline assets
- Patent cliffs (eventual generics/biosimilars)
Phase 3 — Financial Fundamentals
3A — Growth Profile
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | $19.80B | $12.74B | +55.5% |
| Non-GAAP EPS | $8.55 | N/A | Beat $6.79 est |
| Year | Revenue | YoY Growth |
|---|---|---|
| FY2024 | $45.04B | +44.7% |
| FY2025 | $65.18B | +44.7% |
| FY2026E | $85.15B | +30.6% |
| FY2027E | $97.62B | +14.6% |
3B — Profitability & Efficiency
| Metric | Value |
|---|---|
| Gross Margin | ~75%+ |
| Net Margin | ~35% (expanding) |
| ROE | 38.86% |
| EPS TTM | $28.15 (+129.1%) |
3D — Balance Sheet
- Cash: Strong
- Debt: Manageable
- FCF: Robust, growing
- Net Income TTM: $25.28B (+127.6%)
3E — Valuation
| Metric | Value |
|---|---|
| Market Cap | $898B |
| PE TTM | 35.16x |
| Forward PE | 26.61x |
| PS Ratio | 12.31x |
| Forward PS | 10.17x |
| PEG Ratio | 1.23x |
| EV/EBITDA | 25.60x |
Valuation Verdict: PREMIUM BUT JUSTIFIED — At 26.6x forward earnings and 12x sales, LLY trades at a premium to pharma peers. However, the premium is warranted by tirzepatide's $80-100B+ peak sales potential. PEG of 1.23 suggests reasonable value relative to growth rate.
Red Flags
- Concentration risk: tirzepatide franchise is ~80%+ of revenue
- Pricing pressure from PBMs and IRA
- Valuation leaves limited margin of safety
Phase 4 — Catalyst Analysis
Positive Catalysts
| Catalyst | Timing | Probability | Magnitude |
|---|---|---|---|
| Tirzepatide continued +100%+ growth | 2026 | HIGH | Massive |
| Orforglipron Phase 3 data/approval | 2026-2027 | MEDIUM-HIGH | Major upside |
| New tirzepatide indications (MASH, sleep apnea) | 2026-2027 | MEDIUM | Expands franchise |
| Kisunla expansion (Europe, new patients) | 2026 | MEDIUM | Growing franchise |
| Manufacturing capacity doubling | 2026-2027 | HIGH | Supply advantage |
| Q2 2026 earnings beat | Aug 2026 | MEDIUM-HIGH | Re-rate |
Negative Catalysts
| Catalyst | Timing | Probability |
|---|---|---|
| IRA pricing impact | 2026+ | CONFIRMED |
| Novo Nordisk supply improvement | 2026 | MEDIUM |
| Pipeline disappointment | Ongoing | LOW-MEDIUM |
| Competition intensifying | Ongoing | MEDIUM |
Q1 2026 Earnings Recap (April 30, 2026)
- Revenue: $19.80B (+55.5% YoY) — massive beat
- Non-GAAP EPS: $8.55 vs $6.79 estimate (+26% beat)
- Mounjaro: $8.7B (+125% YoY)
- Tirzepatide franchise on track for $80-100B+ peak sales
Phase 5 — Technical & Sentiment Signals
| Metric | Value |
|---|---|
| Current Price | $1,006.46 (+1.67% today) |
| 52-Week High | $1,133.95 |
| 52-Week Low | $623.78 |
| Current vs 52-Week High | -11.2% |
| Beta | 0.48 |
| Avg Daily Volume | ~2-3M shares |
| Institutional Ownership | 90.04% |
Trend: Pulled back ~11% from highs. Currently recovering. Low beta (0.48) makes this a relatively defensive pharma play despite growth.
Key Levels
- Resistance: $1,100, $1,134 (52-week high), $1,200
- Support: $950, $900, $850
Analyst Sentiment
20 analysts covering:
- Strong Buy: 8 | Buy: 10 | Hold: 1 | Sell: 1
- Average target: $1,228 (+22% upside)
- High target: $1,500 (+49% upside)
Recent price target raises (May 2026):
- Barclays: $1,350 (Buy) — +39%
- Morgan Stanley: $1,327 (Buy) — +31.8%
- Wolfe Research: $1,325 (Buy) — +31.6%
- Guggenheim: $1,183 (Strong Buy) — +17.5%
Phase 6 — Risk Assessment & Investment Verdict
Risk Matrix
| Risk Factor | Severity | Likelihood | Mitigation |
|---|---|---|---|
| Valuation compression | MEDIUM | MEDIUM | Long hold horizon |
| Competitive erosion | MEDIUM | MEDIUM | Superior clinical data |
| Pipeline failure | MEDIUM-HIGH | LOW-MEDIUM | Diversified indications |
| IRA pricing headwinds | MEDIUM | CONFIRMED | Limited near-term impact |
| Manufacturing disruption | MEDIUM | LOW | Aggressive capex |
Bull Case ($1,500+)
- Tirzepatide reaches $100B+ peak sales
- Orforglipron (oral GLP-1) approved, capturing oral market
- New indications (MASH, sleep apnea, HFpEF) approved
- FY2027 revenue exceeds $100B, stock rerates to 30x+ → $1,500+
Base Case ($1,100-1,300)
- Tirzepatide grows at 25-30% through 2027
- Pipeline delivers on schedule
- Stock at 28-30x forward earnings → $1,100-1,300
Bear Case ($700-850)
- Competitive pressure intensifies (Novo improves supply, Amgen/Pfizer launch)
- Pricing headwinds worse than expected
- Pipeline disappointments
- Stock compresses to 22-25x → $700-850
Thesis Invalidation Triggers
- Tirzepatide revenue growth decelerates below 20% for two consecutive quarters
- Mounjaro/Zepbound pricing declines more than 20% in a year
- Orforglipron Phase 3 fails or is delayed significantly
Summary
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
STOCK: LLY | PRICE: $1,006.46 | DATE: 2026-05-13
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
MACRO/INDUSTRY: ✅ Strong Tailwind (GLP-1 market expansion)
MOAT: Very Wide (GIP+GLP-1, manufacturing, data)
FINANCIALS: Exceptional (+55.5% Q1 revenue, 35% net margin)
CATALYSTS: Clear (pipeline, new indications, capacity)
TECHNICALS: Constructive (11% pullback, recovering)
VALUATION: Premium but justified (26.6x forward, 1.23x PEG)
OVERALL RATING: 🟢 BUY
ONE-LINE THESIS: LLY's tirzepatide franchise is the most valuable pharmaceutical
asset in decades, with $80-100B+ peak sales potential and multiple expansion
catalysts. The 11% pullback from highs offers an attractive entry for long-term
investors. Maintain as a core healthcare holding.
ENTRY ZONE: $950-1,010 (current range, attractive)
STOP LOSS: $820 (below 200-day MA)
TIME HORIZON: Long-term (3-5 years)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Data Sources: Yahoo Finance, StockAnalysis.com, company Q1 2026 earnings release (April 30, 2026)
Report Date: May 13, 2026
Next Catalyst: Q2 2026 earnings (August 5, 2026)